diflucan 2mg ml infusion - Resultats de la cerca

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

diflucan fluconazole 50 mg/ 5 ml (after reconstitution) powder for oral suspension bottle

pfizer australia pty ltd - fluconazole, quantity: 10 mg/ml - oral liquid, powder for - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; sodium benzoate; xanthan gum; colloidal anhydrous silica; titanium dioxide; flavour - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see adverse reactions). diflucan iv is indicated for the same conditions in adults and children but should be used only when diflucan cannot be administered orally.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

diflucan 40 mg/ml powder for oral suspension

pfizer limited - fluconazole - powder for oral suspension - 40 mg/ml - triazole derivatives

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

diflucan 10 mg/ml powder for oral suspension

pfizer limited - fluconazole - powder for oral suspension - 10 mg/ml - triazole derivatives

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diflucan 2 mg/ml inf. sol. i.v. vial

pfizer sa-nv - fluconazole 200 mg/100 ml - solution for infusion - fluconazole

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

diflucan fluconazole 100 mg capsule blister pack

pfizer australia pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; magnesium stearate; gelatin; lactose monohydrate; maize starch; erythrosine; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten